VISKEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Visken, and what generic alternatives are available?
Visken is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VISKEN is pindolol. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the pindolol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Visken
A generic version of VISKEN was approved as pindolol by AUROBINDO PHARMA USA on September 3rd, 1992.
Summary for VISKEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,284 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | VISKEN at DailyMed |
Recent Clinical Trials for VISKEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Ottawa | Phase 1 |
| University of Aarhus | N/A |
| Danish Cardiovascular Research Academy | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for VISKEN
US Patents and Regulatory Information for VISKEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-001 | Sep 3, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISKEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-001 | Sep 3, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VISKEN
See the table below for patents covering VISKEN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| France | 96640 | ⤷ Sign Up | |
| Romania | 56162 | ⤷ Sign Up | |
| Sweden | 340455 | ⤷ Sign Up | |
| Israel | 31570 | LAEVOROTATORY INDOLE DERIVATIVES,THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Sign Up |
| Switzerland | 453363 | Verfahren zur Herstellung neuer Indolderivate | ⤷ Sign Up |
| Austria | 317199 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
